Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H8N4O3S2 |
| Molecular Weight | 236.272 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O
InChI
InChIKey=FLOSMHQXBMRNHR-QPJJXVBHSA-N
InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+
| Molecular Formula | C5H8N4O3S2 |
| Molecular Weight | 236.272 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00703Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/methazolamide.html
Sources: http://www.drugbank.ca/drugs/DB00703
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/methazolamide.html
Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride. Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Methazolamide is used for treatment of chronic open-angle glaucoma and acute angle-closure glaucoma.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175 |
50.0 nM [Ki] | ||
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175 |
14.0 nM [Ki] | ||
Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175 |
27.0 nM [Ki] | ||
Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175 |
3.4 nM [Ki] | ||
Target ID: CHEMBL2326 Sources: http://www.drugbank.ca/drugs/DB00703 |
2.1 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Methazolamide Approved Useindicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. Launch Date1993 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.5 μg/mL |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
5.1 μg/mL |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
10.7 μg/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1130 μg × min/mL |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
2571 μg × min/mL |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
5418 μg × min/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14 h |
steady-state, oral |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
45% |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
METHAZOLAMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://dmd.aspetjournals.org/content/38/2/347 Page: 348.0 |
no |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy. | 2009-11-01 |
|
| Methazolamide does not impair respiratory work performance in anesthetized rabbits. | 2009-09 |
|
| Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. | 2009-07-15 |
|
| Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. | 2009-07-01 |
|
| Titration calorimetry standards and the precision of isothermal titration calorimetry data. | 2009-06-18 |
|
| Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. | 2009-05-14 |
|
| Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. | 2009-05 |
|
| Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. | 2009-04-23 |
|
| Acetazolamide reversibly inhibits water conduction by aquaporin-4. | 2009-04 |
|
| Studies on bicarbonate transporters and carbonic anhydrase in porcine nonpigmented ciliary epithelium. | 2009-04 |
|
| QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software. | 2009-04 |
|
| Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties. | 2009-02-17 |
|
| Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. | 2009-02-01 |
|
| Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. | 2009-02-01 |
|
| Functional coupling of the downregulated in adenoma Cl-/base exchanger DRA and the apical Na+/H+ exchangers NHE2 and NHE3. | 2009-02 |
|
| CO2 chemosensing in rat oesophagus. | 2008-12 |
|
| Recent advances in pharmacotherapy of glaucoma. | 2008-10 |
|
| Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. | 2008-09-17 |
|
| Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma. | 2008-06 |
|
| Pharmacological impact on loop gain properties to prevent irregular breathing. | 2008-03 |
|
| Carbonic anhydrase II and alveolar fluid reabsorption during hypercapnia. | 2008-01 |
|
| The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. | 2008 |
|
| The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. | 2008 |
|
| Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. | 2007-12-03 |
|
| Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. | 2007-12-01 |
|
| Statement on high-altitude illnesses. An Advisory Committee Statement (ACS). | 2007-04-01 |
|
| Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition. | 2007-04 |
|
| PAT-1 (Slc26a6) is the predominant apical membrane Cl-/HCO3- exchanger in the upper villous epithelium of the murine duodenum. | 2007-04 |
|
| Topical inhibition of nasal carbonic anhydrase affects the CO2 detection threshold in rats. | 2007-03 |
|
| Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy. | 2007-02-15 |
|
| Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. | 2007-01-25 |
|
| The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. | 2007 |
|
| Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. | 2006-10 |
|
| Expression, purification, kinetic, and structural characterization of an alpha-class carbonic anhydrase from Aedes aegypti (AaCA1). | 2006-08 |
|
| The carbonic anhydrase inhibitors methazolamide and acetazolamide have different effects on the hypoxic ventilatory response in the anaesthetized cat. | 2006-07-15 |
|
| Carbonic anhydrases and mucosal vanilloid receptors help mediate the hyperemic response to luminal CO2 in rat duodenum. | 2006-07 |
|
| Degradation and effects of the potential mosquito larvicides methazolamide and acetazolamide in sheepshead minnow (Cyprinodon variegatus). | 2006-07 |
|
| Epithelial carbonic anhydrases facilitate PCO2 and pH regulation in rat duodenal mucosa. | 2006-06-15 |
|
| Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. | 2006-05 |
|
| [Diuretic therapy in heart failure]. | 2006-04-25 |
|
| Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori. | 2006-04-15 |
|
| Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. | 2006-03-23 |
|
| Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study. | 2006-03 |
|
| Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels. | 2006-01 |
|
| Effects of low-dose methazolamide on the control of breathing in cats. | 2006 |
|
| Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. | 2005-11-01 |
|
| Functional interaction of carbonic anhydrase and chloride/bicarbonate exchange in human platelets. | 2005-11 |
|
| Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. | 2005-09-01 |
|
| Carbonic anhydrase in the adult mosquito midgut. | 2005-09 |
|
| Treatment of essential tremor with methazolamide. | 1991-10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/methazolamide.html
Usual Adult Dose for Glaucoma
50 to 100 mg orally 2 or 3 times a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14764447
Methazolamide (0.1 mM) inhibited acid-induced [CO(2)](t) increase in mice.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:35 GMT 2025
by
admin
on
Mon Mar 31 17:50:35 GMT 2025
|
| Record UNII |
W733B0S9SD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
NBK548664
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
||
|
NCI_THESAURUS |
C29577
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
||
|
WHO-VATC |
QS01EC05
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
||
|
WHO-ATC |
S01EC05
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
||
|
NCI_THESAURUS |
C448
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID1023281
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
D008704
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
SUB08843MIG
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
1406005
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
W733B0S9SD
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
29202
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
1741
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
METHAZOLAMIDE
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
6828
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
2101958-72-7
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
ALTERNATIVE | |||
|
209-066-7
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
m7304
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL19
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
882
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
758426
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
3269
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
DB00703
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
6826
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | RxNorm | ||
|
Methazolamide
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
554-57-4
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
100000081410
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
C61318
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
W733B0S9SD
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||